Recursion Pharmaceuticals, Inc. (RXRX) — Stock Price, Chart & Analysis
Recursion Pharmaceuticals, Inc. (RXRX) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $2.17B. Over the past 52 weeks, RXRX has traded between $2.77 and $7.18. Recursion Pharmaceuticals, Inc. does not currently pay a regular dividend. View the live RXRX chart, technical opinion, analyst ratings, fundamentals and latest news below.
Recursion Pharmaceuticals, Inc. (RXRX) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $2.17B |
| EPS (TTM) | $-1.00 |
| 52-week high | $7.18 |
| 52-week low | $2.77 |
| Beta | 1.07 |
| Avg. volume | 19.63M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Recursion Pharmaceuticals, Inc. (RXRX)
How much does one share of Recursion Pharmaceuticals, Inc. cost?
As of the latest update, one share of Recursion Pharmaceuticals, Inc. (RXRX) trades at $100 (+0.00% today).
What is Recursion Pharmaceuticals, Inc.'s market cap?
Recursion Pharmaceuticals, Inc. has a market capitalization of approximately $2.17B.
What is Recursion Pharmaceuticals, Inc.'s earnings per share (EPS)?
Recursion Pharmaceuticals, Inc.'s trailing twelve-month EPS is $-1.00.
Does Recursion Pharmaceuticals, Inc. pay a dividend?
Recursion Pharmaceuticals, Inc. does not currently pay a regular dividend.
What is Recursion Pharmaceuticals, Inc.'s 52-week trading range?
Over the past year, RXRX has traded between $2.77 and $7.18.
What is the analyst price target for Recursion Pharmaceuticals, Inc.?
The mean analyst price target for Recursion Pharmaceuticals, Inc. is $7.22. This is informational only and not investment advice.
Latest Recursion Pharmaceuticals, Inc. (RXRX) news
- Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley ConferenceNews · Sep 21, 2026
- Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?News · Sep 19, 2026
- Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to KnowNews · Sep 16, 2026
- The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and AbsciNews · Aug 18, 2026
- Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley SaysNews · Aug 17, 2026
- Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline UpdatesNews · Aug 17, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live RXRX dashboard…